期刊文献+
共找到681篇文章
< 1 2 35 >
每页显示 20 50 100
Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers 被引量:3
1
作者 武静 王本杰 +2 位作者 魏春敏 卜凡龙 郭瑞臣 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第3期192-196,共5页
Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.... Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm ×150 mm) column and a mobile phase of methanol: 0.01 mol·L^-1ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9 [M+H]^+ for nifedipine, and 320.8 [M+H]^+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax(39.66 ± 10.58) ng·mL^-1 and (40.19 ± 10.97) ng·mL^-1, AUC0-36 (391.63 ± 108.55) ng·mL^-1·h and (387.57 ± 121.51) ng·mL^-1·h, and AUC0-∞ (408.28 ± 121.16) ng·mL^-1·h and (406.15 ± 133.13) ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies. 展开更多
关键词 nifedipine sustained-release tablets LC-MS PHARMACOKINETICS BIOEQUIVALENCE
下载PDF
Evaluation Procedure for Quality Consistency of Generic Nifedipine Extended-Release Tablets Based on the Impurity Profile 被引量:1
2
作者 Ming-Yuan Zhang Jun-Dong Zhang +2 位作者 Qun Gao Yan Liu Feng Lu 《American Journal of Analytical Chemistry》 2015年第9期776-785,共10页
A procedure to evaluate the quality consistency of generic drugs based on the impurity profile and the similarity analysis methods was presented in this paper. Nifedipine extended-release tablets from six generic fact... A procedure to evaluate the quality consistency of generic drugs based on the impurity profile and the similarity analysis methods was presented in this paper. Nifedipine extended-release tablets from six generic factories of China were used to evaluate the uniformity with the original drug in the study. The procedure includes: choice of chromatographic methods, data collection and conformity test, evaluation of intra-batch similarity of drugs, evaluation of generic drugs with the original drug and weighted similarity evaluation of generic drugs. The data were collected via high-performance liquid chromatography (HPLC), and then calculated by correlation coefficient, cosine, principal component analysis (PCA) and hierarchical clustering analysis (HCA). It is more suitable to use peak areas as the vector when calculating the similarity of impurity profile. After weighting the peak areas of the unspecified impurities in further evaluation of the generic quality, the generic level of different factories was differentiated and the best generic factory was picked out. 展开更多
关键词 Impurity Profile CHEMOMETRICS nifedipine EXTENDED-RELEASE tablets Weighting CONSISTENCY EVALUATION
下载PDF
Preparation and <i>in Vitro</i>Drug Release Evaluation of Once-Daily Metformin Hydrochloride Sustained-Release Tablets 被引量:1
3
作者 Ling Zhao Yumeng Wei +4 位作者 Yong Mei Li Yang Yuan You Xufeng Yang Yanhong Jiang 《Pharmacology & Pharmacy》 2012年第4期468-473,共6页
The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitr... The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitro drug release rate of MHSRT and the commercial tablets Fortamet? made in the United States of America in water was fitted with zero order kinetic equation, and Ritger-Peppas kinetic equation in 0.1 M HCl and pH 6.8-phosphate buffer, respectively. The similarity factor f2 values of MHSRT in three different dissolution medium were 82, 80 and 74, respectively in comparison with imported Fortamet?, which were all greater than 50. The results of storage-stability showed that MHSRT were stable for at least 6 months under stress condition (40℃ ± 2℃, RH 75% ± 5%). Therefore, in this study, MHSRT were successfully prepared using optimized formulation technologies that meet mass produce. The in vitro release behavior of MHSRT was almost similar to that of imported Fortamet?. 展开更多
关键词 sustained-release tablets METFORMIN HYDROCHLORIDE In Vitro Release Rate Similarity Factor Kinetic Model
下载PDF
Preparation and evaluation of sustained-release azithromycin tablets in vitro and in vivo
4
作者 Le Sun Weixiang Zhang +1 位作者 Xiaohong Liu Jin Sun 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2014年第3期155-161,共7页
The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.... The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.AZI sustained-release tablets with different release performance(F-I:T_(100%)=3 h and F-II:T_(100%)=8 h in pH 6.0 phosphate buffer)were successfully prepared by wet granulation.The in vitro release rate and drug release mechanism were studied.The release rate of F-Iwas affected by dissolutionmedia with different pH,but not for F-II.HixsoneCrowellmodel was the best regression fitting model for F-I and F-II.Additionally,F-I and F-II both belonged to non-Fick diffusion.Oral pharmacokinetics of the two tablets and one AZI dispersible tablet as reference were studied in six healthy beagle dogs after oral administration.Compared with the reference,the C_(max) of F-I and F-II were decreased,and the T_(max) were prolonged,in that case which meet the requirement of sustained-release tablets.The relative bioavailability of F-I and F-II were 79.12%and 64.09%.T-test ofAUC_(0-144),and AUC_(0-∞) for F-I and F-II indicated there was no significant difference between F-I and F-II.These mean that the extended release rate did not induce different pharmacokinetics in vivo. 展开更多
关键词 AZITHROMYCIN sustained-release tablet PHARMACOKINETICS UPLC-MS-MS
下载PDF
Formulation development of nifedipine controlled-release coated tablets
5
作者 Ananya Ubonratana Sirachaya Choosakul +2 位作者 Nara Nilnakara Chaisan Sriwichupong Garnpimol Ritthidej 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2016年第1期118-119,共2页
Due to frequent administration of oral nifedipine tablet, controlled or sustained release of the drug will improve patient compliance, stable blood level and side effect decrement [1,2].Various extended release nifedi... Due to frequent administration of oral nifedipine tablet, controlled or sustained release of the drug will improve patient compliance, stable blood level and side effect decrement [1,2].Various extended release nifedipine products have been commercially available. In this study, extended release tablets of this drug were formulated using sodium alginate,hydroxypropylmethylcellulose (HPMC) as controlled release matrix materials. 展开更多
关键词 nifedipine Extended release tablet Matrix SODIUM ALGINATE HPMC
下载PDF
Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis
6
作者 Qian-Zhang Ma Yun Li Yuan-Quan Ding 《Journal of Hainan Medical University》 2019年第12期37-42,共6页
Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and ser... Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and serum inflammatory factors.Methods: A total of 84 patients with ulcerative colitis were randomly divided into control group and treatment group, with 42 cases in each group. The control group was given mesalazine sustained-release tablets orally, while the treatment group was given Baitou Weng Decoction and mesalazine sustained-release tablets orally. The treatment period was 30 days and the patients were followed up for 3 months. After treatment, the clinical efficacy, quality of life, immune function and serum inflammatory factors of the two groups were observed.Results: The effective rate of treatment group (90.47%) was higher than that of control group (73.81%) (P<0.05);compared with before treatment, the scores of inflammatory bowel disease quality of life questionnaire scale in both groups were significantly improved (P<0.05), and the difference between the two groups was significant (P<0.05);after treatment, the plasma CD4+/CD8+ ratio and NK+ levels in both groups were significantly higher than those before treatment (P<0.05), and the treatment group was changed. The serum levels of tumor necrosis factor-α, interleukin-17 and interleukin-23 were significantly decreased in both groups after treatment (P<0.05), and the improvement was more significant in the treatment group (P<0.05). No significant adverse reactions were observed in the treatment group.Conclusions: Modified Baitou Weng Decoction combined with mesalazine in the treatment of heat-toxic and incandescent ulcerative colitis can significantly improve the clinical efficacy, improve the quality of life of patients, effectively regulate the expression level of serum inflammatory factors in ulcerative colitis patients, promote the recovery of patients' immune function, and have high drug safety. 展开更多
关键词 Baitou WENG DECOCTION MESALAZINE sustained-release tablets Hot toxicity ULCERATIVE colitis Immune function Serum inflammatory factor
下载PDF
Clinical observation on treatment of cancer pain with TCM oriented drugs combined with oxycodone sustained-release tablets and nimesulide sustained-release tablets
7
作者 Feng-Jiao He Ke-Xiong Li +2 位作者 Pu-Hua Zeng Hai-Yan Yi Xiao-Lan Jian 《TMR Cancer》 2018年第4期118-123,共6页
Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divi... Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divided into 4 groups, 39 patients in group A (directed TCM permeation), 26 patients in group B (oxycodone sustained-release tablets), 32 patients in group C (Chinese medicine directed drug penetration + oxycodone sustained-release tablets), and 29 patients group D (Chinese medicine directed drug penetration + oxycodone sustained-release tablets + nimesulide sustained release tablets), according to KPS scores. Results: Transdermal preparations of traditional Chinese medicine can significantly alleviate cancer pain. For the treatment of moderate to severe cancer pain, the Chinese medicine transdermal preparation can reduce the dosage of oxycodone sustained-release tablets. At the same time, the patient's KPS and NRS scores were significantly reduced. Moreover, the transdermal preparation of traditional Chinese medicine has a better therapeutic effect on visceral pain. Conclusion: The traditional Chinese medicine tra_nsdermal preparation combined with western medicine for the treatment of cancer pain may be a new method for the treatment of cancer pain. 展开更多
关键词 Chinese medicine directed drug Oxycodone sustained-release tablets Cancer pain Clinical efficacy
下载PDF
Pharmacokinetic Study on Lovastatin Sustained-release Tablet and Sustained-release Capsule in Begal Dogs
8
作者 付琳 代宗顺 +1 位作者 侯淑贤 万元胜 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2004年第2期116-119,共4页
This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagl... This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h. 展开更多
关键词 LOVASTATIN sustained-release tablets sustained-release capsules PHARMACOKINETIC SINGLE-DOSE MULTIPLE-DOSE
下载PDF
Simultaneous Analysis of Indapamide and Related Impurities in Sustained-Release Tablets by a Single-Run HPLC-PDA Method
9
作者 YAO Wu ZHOU Shiwen CHENG Qiongru 《Wuhan University Journal of Natural Sciences》 CAS CSCD 2023年第4期333-340,共8页
The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array dete... The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)method for the quality control in this paper.The results showed the method had a good selectivity and was validated through linearity,limits of detection and quantification,recovery,and precision.The linear ranges of indapamide,2-methyl-1-nitroso-2,3-dihydro-1H-indole(impurity A,ImA),4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulphamoyl-benzamide(impurity B,ImB)and 4-chloro-3-sulfamoylbenzoic acid(impurity 1,Im1)were 0.028-1.80μg/mL(R=0.99995),0.060-1.20μg/mL(R=0.9996),0.0324-1.20μg/mL(R=0.99985)and 0.060-1.20μg/mL(R=0.9997)with detection limits of 0.0093,0.012,0.012 and 0.006μg/mL,respectively.ImA and Im1 were not detectable in the generic drug.The content of indapamide was 96.7%of the labeled amount with a relative standard deviation(RSD)of 1.30%,and the percentage of ImB relative to the labeled amounts of indapamide was 0.106%with an RSD of 1.82%.The content of other unspecified impurities all met the reference quality standards.The results provided references for the quality control and the quality standard study of generic indapamide sustained-release tablets. 展开更多
关键词 INDAPAMIDE related impurity sustained-release tablets high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)
原文传递
沙库巴曲缬沙坦联合硝苯地平控释片治疗2型糖尿病肾病合并高血压患者的临床效果 被引量:1
10
作者 陆勇良 林秋伟 +3 位作者 韦广 何赣维 汤展 刘成彬 《中国医药科学》 2024年第3期124-127,共4页
目的 探究沙库巴曲缬沙坦联合硝苯地平控释片对2型糖尿病肾病合并高血压患者的治疗效果。方法 选取2022年1月至2023年1月高州市人民医院收治的2型糖尿病肾病合并高血压患者100例,以随机数表法将其分为两组,对照组给予缬沙坦80 mg qd与... 目的 探究沙库巴曲缬沙坦联合硝苯地平控释片对2型糖尿病肾病合并高血压患者的治疗效果。方法 选取2022年1月至2023年1月高州市人民医院收治的2型糖尿病肾病合并高血压患者100例,以随机数表法将其分为两组,对照组给予缬沙坦80 mg qd与硝苯地平控释片30 mg qd降压治疗,观察组给予沙库巴曲缬沙坦200 mg qd与硝苯地平控释片30 mg qd降压治疗,比较两组患者治疗前后血压、血糖、肾功能指标、血管内皮相关因子及炎性因子变化情况,同时观察两组患者不良反应的发生情况。结果 观察组治疗后血压、空腹血糖、糖化血红蛋白低于对照组,差异有统计学意义(P <0.05);观察组治疗后肌酐、尿素氮、尿微量白蛋白、胱抑素C水平低于对照组,差异有统计学意义(P <0.05);观察组治疗后血管紧张素Ⅱ、超敏C反应蛋白、白介素-6水平低于对照组,差异有统计学意义(P <0.05);两组不良反应总发生率比较,差异无统计学意义(P> 0.05)。结论 沙库巴曲缬沙坦联合硝苯地平控释片对于2型糖尿病肾病合并高血压的患者的治疗效果较好,可较好地控制血压和血糖水平,减缓患者肾功能衰竭进程。 展开更多
关键词 沙库巴曲缬沙坦 硝苯地平控释片 2型糖尿病肾病合并高血压 临床效果
下载PDF
硝苯地平片+硫酸镁治疗妊娠期高血压疾病的疗效及对患者血压和预后的影响
11
作者 刘菊菊 《中外医疗》 2024年第4期119-121,134,共4页
目的探讨硝苯地平片结合硫酸镁治疗妊娠期高血压的效果及对患者血压和预后的影响。方法简单随机选取2021年8月-2023年8月南京医科大学附属妇产医院(南京市妇幼保健院)收治的70例妊娠期高血压患者为研究对象,按随机数表法分成两组,每组3... 目的探讨硝苯地平片结合硫酸镁治疗妊娠期高血压的效果及对患者血压和预后的影响。方法简单随机选取2021年8月-2023年8月南京医科大学附属妇产医院(南京市妇幼保健院)收治的70例妊娠期高血压患者为研究对象,按随机数表法分成两组,每组35例。对照组给予硫酸镁治疗,观察组在对照组治疗基础上联用硝苯地平片治疗。对比两组患者的治疗效果。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组血压水平比较,差异无统计学意义(P>0.05);治疗后两组血压水平均有改善,且观察组血压改善程度优于对照组,差异有统计学意义(P<0.05)。在分娩方式对比中,观察组自然分娩率较对照组更高,差异有统计学意义(P<0.05);两组剖宫产率比较,差异无统计学意义(P>0.05)。在新生儿并发症发生率对比中,观察组胎儿窘迫发生率较对照组更低,差异有统计学意义(P<0.05);两组新生儿窒息率和死亡率比较,差异无统计学意义(P均>0.05)。结论硝苯地平片联合硫酸镁可提高妊娠期高血压患者的治疗结果,可有效将患者血压水平予以降低,并提高自然分娩率,且安全性较高。 展开更多
关键词 妊娠期高血压 硝苯地平片 硫酸镁 预后
下载PDF
凉血十味片联合硝苯地平缓释片治疗原发性高血压性视网膜病变临床观察
12
作者 李强 《光明中医》 2024年第6期1175-1177,共3页
目的探究凉血十味片联合硝苯地平缓释片治疗原发性高血压性视网膜病变(HR)的疗效及安全性。方法选取HR患者100例,按照随机数字表法分为治疗组(凉血十味片+硝苯地平缓释片)及对照组(硝苯地平缓释片),各50例,对比2组临床疗效。结果治疗组... 目的探究凉血十味片联合硝苯地平缓释片治疗原发性高血压性视网膜病变(HR)的疗效及安全性。方法选取HR患者100例,按照随机数字表法分为治疗组(凉血十味片+硝苯地平缓释片)及对照组(硝苯地平缓释片),各50例,对比2组临床疗效。结果治疗组总有效率高于对照组(P<0.05);治疗后,治疗组血压、视力、眼底改变情况、眼底荧光素血管造影情况、中医证候积分均优于对照组(P<0.05)。结论凉血十味片联合硝苯地平缓释片治疗HR疗效确切,能有效提升患者视力,提高患者视觉质量,且无不良反应,安全有效。 展开更多
关键词 视瞻昏渺 原发性高血压性视网膜病变 凉血十味片 硝苯地平缓释片 中西医结合疗法
下载PDF
基于体外溶出评价方法对硝苯地平缓释片(Ι)一致性评价研究
13
作者 牟聪 徐有坤 吴青青 《山东化工》 CAS 2024年第5期34-37,40,共5页
建立硝苯地平缓释片(Ⅰ)体外溶出评价方法,以原研制剂为参比,评价本公司一致性研究前后的自研制剂(以下简称自制1、自制2),为质量一致性提供依据。选取0.3%吐温80的不同pH值(pH值1.0,pH值4.0,pH值6.8,水)溶液为溶出介质,采用高效液相色... 建立硝苯地平缓释片(Ⅰ)体外溶出评价方法,以原研制剂为参比,评价本公司一致性研究前后的自研制剂(以下简称自制1、自制2),为质量一致性提供依据。选取0.3%吐温80的不同pH值(pH值1.0,pH值4.0,pH值6.8,水)溶液为溶出介质,采用高效液相色谱法考察0.25,0.5,1,2,3,10,12 h的释放度,从而建立体外溶出曲线方法,并进行了方法学验证,最后采用相似因子法(f_(2))将自研制剂与参比进行比较。结果表明,建立的本品体外溶出曲线方法的专属性、线性、精密度、准确度、滤膜吸附、溶液稳定性各项指标均符合要求;自制1与参比溶出行为不一致且f_(2)小于50,调整处方工艺后,自制2与参比体外溶出行为一致,且f_(2)均大于50。本品建立的体外溶出评价方法准确可靠,自制1与参比体外溶出不一致;自制2与参比溶出曲线相似,体外溶出一致。 展开更多
关键词 硝苯地平缓释片(Ι) 体外溶出 仿制药一致性评价 相似因子法
下载PDF
Qualitative and quantitative analysis of HPLC fingerprint of Wuji gastric floating sustained-release tablets 被引量:1
14
作者 陈中芬 刘文 +2 位作者 陈大业 施晓伟 王群 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第5期310-317,共8页
A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 co... A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 column (250 mm×4.6 mm, 5 μm) as the chromatographic column, and acetonitrile-0.05 mol/L potassium dihydrogen phosphate solution as the mobile phase in a gradient elution with the flow rate of 1.0 mL/min. Sample solution (10 μL) was injected and was tested at the wavelength of 225 nm for 75 min at the column temperature of 30 ℃, Fingerprint similarity software (2004A version) was used to conduct data analysis. A total of 11 batches of Wuji gastric floating sustained-release tablets were tested and analyzed with HPLC fingerprint. Seventeen common peaks were found and the similarity of the 11 batches of agents was greater than 0.9, indicating that the production process of the agent is stable and feasible. The method is operable and could effectively control the quality of Wuji gastric floating sustained-release tablets. 展开更多
关键词 FINGERPRINT HPLC Wuji gastric floating sustained-release tablets
原文传递
冠心苏合胶囊联合硝苯地平控释片治疗不稳定型心绞痛的临床效果研究 被引量:1
15
作者 刘洋 《中国医药》 2024年第4期589-592,共4页
目的 探讨冠心苏合胶囊联合硝苯地平控释片治疗不稳定型心绞痛(UAP)的临床效果。方法 将2021年5月到2023年5月在黑龙江省第二医院接受治疗的104例UAP患者按随机数字表法分为观察组(52例)和对照组(52例)。对照组口服硝苯地平控释片进行治... 目的 探讨冠心苏合胶囊联合硝苯地平控释片治疗不稳定型心绞痛(UAP)的临床效果。方法 将2021年5月到2023年5月在黑龙江省第二医院接受治疗的104例UAP患者按随机数字表法分为观察组(52例)和对照组(52例)。对照组口服硝苯地平控释片进行治疗,观察组口服冠心苏合胶囊以及硝苯地平控释片进行治疗。在治疗30 d后进行疗效评价,比较2组患者治疗前后的血清炎症因子和血液流变学指标,比较2组患者的不良反应发生情况。结果 观察组总有效率高于对照组[94.2%(49/52)比80.8%(42/52)],差异有统计学意义(P=0.038)。治疗30 d后,2组患者血清基质金属蛋白酶9、白细胞介素18、C反应蛋白水平均明显低于治疗前,且观察组均低于对照组(均P<0.05)。治疗30 d后,2组患者纤维蛋白原、低切全血黏度、中切全血黏度、高切全血黏度、血浆黏度均明显低于治疗前,且观察组均低于对照组(均P<0.05)。对照组不良反应发生率与观察组比较[5.8%(3/52)比9.6%(5/52)],差异无统计学意义(P=0.713)。结论 冠心苏合胶囊联合硝苯地平控释片治疗UAP具有较好的临床效果,可有效改善患者的炎症状态和血液高凝状态,且安全性较好。 展开更多
关键词 不稳定型心绞痛 冠心苏合胶囊 硝苯地平控释片
下载PDF
基于硝苯地平控释片体外研究预测制剂的生物等效性
16
作者 牟聪 王东凯 《中国药剂学杂志(网络版)》 2024年第4期123-130,共8页
目的基于对硝苯地平控释片自制的放大样品与参比制剂的溶出结果,通过药物溶出度及渗透速率测试系统预测体内外的一致性。方法首先,对比研究了自制硝苯地平控释片与参比制剂(拜新同)的溶出曲线;再采用MacroFlux型药物溶出度及渗透速率测... 目的基于对硝苯地平控释片自制的放大样品与参比制剂的溶出结果,通过药物溶出度及渗透速率测试系统预测体内外的一致性。方法首先,对比研究了自制硝苯地平控释片与参比制剂(拜新同)的溶出曲线;再采用MacroFlux型药物溶出度及渗透速率测试系统测定了硝苯地平控释片在空腹小肠模拟液(pH6.5)中的渗透速率以及渗透量;对比研究了参比制剂与受试制剂的释放与吸收过程。结果自制硝苯地平控释片在4种溶出介质中的溶出行为与参比制剂相似,药物体外溶出度—渗透速率测试结果显示,受试制剂溶出速率以及渗透速率均与参比制剂接近,最终与参比制剂生物等效。结论硝苯地平控释片结合体外溶出和药物溶出度及渗透速率测试系统的结果,可以快速预测评价受试制剂的生物等效性情况,为仿制药在人体的生物等效性评价提供了有力的技术支撑。 展开更多
关键词 硝苯地平 控释片 溶出 渗透 体外模拟
下载PDF
硝苯地平控释片联合厄贝沙坦氢氯噻嗪治疗社区中重度高血压的临床疗效研究 被引量:1
17
作者 余丽丹 《中国医药指南》 2024年第9期110-112,124,共4页
目的探讨对于社区中重度高血压患者实施硝苯地平控释片联合厄贝沙坦氢氯噻嗪方案进行治疗的效果。方法选取社区服务中心在2021年3月至2023年3月此阶段内就诊的中重度高血压患者,以其中100例进行随机分组研究,对照组50例以硝苯地平控释... 目的探讨对于社区中重度高血压患者实施硝苯地平控释片联合厄贝沙坦氢氯噻嗪方案进行治疗的效果。方法选取社区服务中心在2021年3月至2023年3月此阶段内就诊的中重度高血压患者,以其中100例进行随机分组研究,对照组50例以硝苯地平控释片治疗,观察组50例在对照组基础上联合厄贝沙坦氢氯噻嗪,对两组血压控制情况,安全性等进行比较。结果治疗前,两组血压水平比较差异不明显(P>0.05);经干预后均改善,且观察组治疗后的DBP、SBP水平低于对照组(P<0.05);观察组经联合治疗后其血压得到良好控制,其总有效率达到96.00%较对照组高(P<0.05);在治疗后的生活质量方面方面,观察组干预后的生活质量得分多于对照组(P<0.05);药物安全性方面,观察组出现不良反应发生率较对照组要低(P<0.05)。结论对于社区收治的中重度高血压患者,采取硝苯地平控释片联合厄贝沙坦氢氯噻嗪治疗方案,效果肯定,血压控制率良好,且进一步降低血压水平,提高生活质量,且降低用药期间不良反应发生率。 展开更多
关键词 硝苯地平控释片 厄贝沙坦氢氯噻嗪 社区 中重度高血压 临床疗效
下载PDF
增强型体外反搏联合硝苯地平控释片治疗老年单纯收缩期高血压的效果 被引量:1
18
作者 刘爽 卢江曼 +1 位作者 张刚 杨云 《河北医药》 CAS 2024年第12期1834-1837,共4页
目的 分析探讨增强型体外反搏联合硝苯地平控释片治疗老年单纯收缩期高血压的效果。方法 选取2021年3月至2022年12月收治的80例老年单纯收缩期高血压老年患者为研究对象,随机分为对照组和观察组,每组40例。对照组以硝苯地平控释片治疗,... 目的 分析探讨增强型体外反搏联合硝苯地平控释片治疗老年单纯收缩期高血压的效果。方法 选取2021年3月至2022年12月收治的80例老年单纯收缩期高血压老年患者为研究对象,随机分为对照组和观察组,每组40例。对照组以硝苯地平控释片治疗,观察组增加增强型体外反搏治疗。疗程结束后评估患者的临床疗效、血压波动性、肾功能指标、生活质量评分、治疗安全性。结果 观察组总有效率为92.50%,高于对照组的75.00%(P<0.05)。治疗后,观察组患者24 h平均收缩压(24 h mSBP)、24 h动态血压标准差(SD)、24 h动态血压变异系数(CV)均低于对照组(P<0.05)。治疗后,观察组尿微量白蛋白(MAU)、尿肌酐清除率(UCr)、尿微量白蛋白/肌酐比值(ACR)均低于对照组(P<0.05)。治疗后,观察组生活质量综合评定问卷(GQOLI-74)各项评分高于对照组(P<0.05)。2组不良反应发生率为15.00%(6/40)、10.00%(4/40),差异无统计学意义(P>0.05)。结论 增强型体外反搏联合硝苯地平控释片治疗老年单纯收缩期高血压的效果良好,可降低患者血压波动性,改善患者肾功能指标,提高患者的日常生活质量水平,有较好的安全性,可在临床推广应用。 展开更多
关键词 收缩期高血压 硝苯地平控释片 增强型体外反搏 血压波动 肾功能 生活质量
下载PDF
小剂量酒石酸美托洛尔片联合硝苯地平控释片治疗中青年高血压患者的有效性与安全性
19
作者 董博飞 李静宇 +1 位作者 常凤军 李康 《临床医学研究与实践》 2024年第12期56-59,68,共5页
目的 分析小剂量酒石酸美托洛尔片联合硝苯地平控释片治疗中青年高血压患者的有效性与安全性。方法 选取2019年1月至2021年12月收治的80例中青年高血压患者为研究对象,以随机数字表法将其分为常规组(40例,常规剂量酒石酸美托洛尔片+硝... 目的 分析小剂量酒石酸美托洛尔片联合硝苯地平控释片治疗中青年高血压患者的有效性与安全性。方法 选取2019年1月至2021年12月收治的80例中青年高血压患者为研究对象,以随机数字表法将其分为常规组(40例,常规剂量酒石酸美托洛尔片+硝苯地平控释片治疗)和观察组(40例,小剂量酒石酸美托洛尔片+硝苯地平控释片治疗)。比较两组的治疗效果。结果 观察组的治疗总有效率高于常规组(P<0.05)。治疗后,观察组的收缩压(SBP)、舒张压(DBP)及总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平低于常规组,高密度脂蛋白胆固醇(HDL-C)水平高于常规组(P<0.05)。治疗后,观察组的血栓调节蛋白(TM)、内皮素(ET)、脑钠肽(BNP)、血管紧张素Ⅱ(AgⅡ)及基质金属蛋白酶-9(MMP-9)水平低于常规组(P<0.05)。观察组治疗期间的不良反应总发生率低于常规组(P<0.05)。结论 小剂量酒石酸美托洛尔片联合硝苯地平控释片治疗中青年高血压患者安全且高效。 展开更多
关键词 高血压 中青年 小剂量酒石酸美托洛尔片 硝苯地平控释片 血脂 安全性
下载PDF
替米沙坦联合硝苯地平控释片对冠心病合并轻中度高血压患者左心室功能及炎症反应的影响
20
作者 刘爱霞 《中国实用医药》 2024年第5期104-106,共3页
目的探究冠心病合并轻中度高血压患者采用替米沙坦+硝苯地平控释片治疗对患者左心室功能及炎症反应的影响。方法选择108例冠心病合并轻中度高血压患者,按随机数字表法分为对照组和观察组,各54例。对照组给予硝苯地平控释片治疗,观察组... 目的探究冠心病合并轻中度高血压患者采用替米沙坦+硝苯地平控释片治疗对患者左心室功能及炎症反应的影响。方法选择108例冠心病合并轻中度高血压患者,按随机数字表法分为对照组和观察组,各54例。对照组给予硝苯地平控释片治疗,观察组在对照组基础上加用替米沙坦治疗。比较两组血压[舒张压(DBP)及收缩压(SBP)]、心功能[左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)]、炎症反应[肿瘤坏死因子-α(TNF-α)及超敏C反应蛋白(hs-CRP)]及安全性。结果治疗前,两组DBP、SBP比较,差异无统计学意义(P>0.05);治疗后,观察组DBP(78.22±6.79)mm Hg(1mm Hg=0.133 kPa)、SBP(124.14±9.95)mm Hg均低于对照组的(84.57±8.02)、(140.69±11.20)mm Hg,差异有统计学意义(P<0.05)。治疗前,两组LVEDD、LVEF、LVESD比较,无统计学差异(P>0.05);治疗后,观察组LVEDD(51.43±6.13)mm、LVESD(43.13±6.97)mm均小于对照组的(54.13±5.89)、(46.42±6.95)mm,LVEF(52.84±7.46)%大于对照组的(49.48±6.97)%,有统计学差异(P<0.05)。治疗前,两组TNF-α、hs-CRP水平比较,差异无统计学意义(P>0.05);治疗后,观察组TNF-α(39.38±9.85)ng/L、hs-CRP(6.32±0.88)mg/L均低于对照组的(51.29±8.38)ng/L、(8.98±1.28)mg/L,差异有统计学意义(P<0.05)。两组均未出现严重不良反应。结论冠心病合并轻中度高血压患者采用替米沙坦联合硝苯地平控释片治疗能够有效缓解炎症反应,调节血压,改善心功能,且安全性高。 展开更多
关键词 冠心病 轻中度高血压 替米沙坦 硝苯地平控释片 心功能 炎症反应
下载PDF
上一页 1 2 35 下一页 到第
使用帮助 返回顶部